Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

LP Jordheim, D Durantel, F Zoulim… - Nature reviews Drug …, 2013 - nature.com
Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

LP Jordheim, P Sève, O Trédan, C Dumontet - The lancet oncology, 2011 - thelancet.com
The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of
cell proliferation, cell migration, tumour and metastasis development, and the synthesis of …

Review of recent studies on resistance to cytotoxic deoxynucleoside analogues

LP Jordheim, C Dumontet - Biochimica et Biophysica Acta (BBA)-Reviews …, 2007 - Elsevier
Cytotoxic deoxynucleoside analogues are widely used in the treatment of haematological
malignancies and solid tumours. Their metabolism and mechanisms of action are relatively …

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma

…, T André, C Dumontet, CE Cass, LP Jordheim… - Gastroenterology, 2012 - Elsevier
BACKGROUND & AIMS: Patients who undergo surgery for pancreatic ductal adenocarcinoma
(PDAC) frequently receive adjuvant gemcitabine chemotherapy. Key determinants of …

[HTML][HTML] The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent

…, D Mathe, A Tourette, L Serre, LP Jordheim… - Frontiers in …, 2018 - frontiersin.org
In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors
(ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine …

Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells

LP Jordheim, KH Barakat, L Heinrich-Balard… - Molecular …, 2013 - ASPET
The benefit of cancer chemotherapy based on alkylating agents is limited because of the
action of DNA repair enzymes, which mitigate the damage induced by these agents. The …

[HTML][HTML] Hybrid core-shell particles for mRNA systemic delivery

…, T Granjon, H Zhang, K Remaut, LP Jordheim… - Journal of Controlled …, 2023 - Elsevier
mRNA based infectious disease vaccines have opened the venue for development of novel
nucleic acids-based therapeutics. For all mRNA therapeutics dedicated delivery systems are …

Nano-encapsulation of Vitamin D3 Active Metabolites for Application in Chemotherapy: Formulation Study and in Vitro Evaluation

E Almouazen, S Bourgeois, LP Jordheim, H Fessi… - Pharmaceutical …, 2013 - Springer
… At 4, 7 and 10 days after the initiation of treatment, cell proliferation was determined using
the MTT assay as described earlier by Jordheim et al. (24). Three individual experiments were …

Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry

S Cohen, M Megherbi, LP Jordheim, I Lefebvre… - … of chromatography B, 2009 - Elsevier
In this study, we developed a new method for the simultaneous determination of eight
endogenous ribonucleoside triphosphates and deoxyribonucleoside triphosphates based on a …

[HTML][HTML] Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction

KH Barakat, LP Jordheim, R Perez-Pineiro, D Wishart… - PLoS …, 2012 - journals.plos.org
Background Nucleotide excision repair (NER) removes many types of DNA lesions including
those induced by UV radiation and platinum-based therapy. Resistance to platinum-based …